MY129491A - Hydrazono-malonitriles - Google Patents

Hydrazono-malonitriles

Info

Publication number
MY129491A
MY129491A MYPI20024107A MYPI20024107A MY129491A MY 129491 A MY129491 A MY 129491A MY PI20024107 A MYPI20024107 A MY PI20024107A MY PI20024107 A MYPI20024107 A MY PI20024107A MY 129491 A MY129491 A MY 129491A
Authority
MY
Malaysia
Prior art keywords
hydrazono
malonitriles
diseases
cachexia
tumours
Prior art date
Application number
MYPI20024107A
Other languages
English (en)
Inventor
Hans-Michael Dr Eggenweiler
Michael Dr Wolf
Nobert Dr Beier
Pierre Prof Dr Schelling
Thomas Dr Ehring
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MY129491A publication Critical patent/MY129491A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
MYPI20024107A 2001-11-05 2002-11-01 Hydrazono-malonitriles MY129491A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01125455 2001-11-05

Publications (1)

Publication Number Publication Date
MY129491A true MY129491A (en) 2007-04-30

Family

ID=8179075

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20024107A MY129491A (en) 2001-11-05 2002-11-01 Hydrazono-malonitriles

Country Status (19)

Country Link
US (2) US7141572B2 (enExample)
EP (1) EP1441730B1 (enExample)
JP (1) JP5116940B2 (enExample)
KR (1) KR100898894B1 (enExample)
CN (1) CN1585641A (enExample)
AR (1) AR040629A1 (enExample)
AT (1) ATE335486T1 (enExample)
AU (1) AU2002363368B2 (enExample)
BR (1) BR0213683A (enExample)
CA (1) CA2465746C (enExample)
DE (1) DE60213841T2 (enExample)
ES (1) ES2268157T3 (enExample)
HU (1) HUP0401747A3 (enExample)
MX (1) MXPA04004263A (enExample)
MY (1) MY129491A (enExample)
PL (1) PL369738A1 (enExample)
RU (1) RU2302412C2 (enExample)
WO (1) WO2003039548A1 (enExample)
ZA (1) ZA200404387B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
JPWO2004087641A1 (ja) * 2003-03-31 2006-06-29 第一製薬株式会社 ヒドラゾン誘導体
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
RS52944B (sr) * 2005-04-19 2014-02-28 Takeda Gmbh Roflumilast za lečenje pulmonarne hipertenzije
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2648036C (en) 2006-03-31 2012-05-22 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
JP6063123B2 (ja) 2008-11-15 2017-01-18 メリンタ セラピューティクス、インク 抗菌性組成物
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
US8440655B2 (en) * 2010-06-21 2013-05-14 Theracos, Inc. Combination therapy for the treatment of diabetes
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
ES2773543T3 (es) * 2013-03-06 2020-07-13 Janssen Pharmaceutica Nv Benzoimidazol-2-ilpirimidinas moduladores del receptor de histamina H4
WO2015054359A1 (en) * 2013-10-08 2015-04-16 Ebadi Mark A Methods and compositions for symptomatic reflief of the common cold
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
AU2015298378B2 (en) 2014-08-06 2018-08-02 Pfizer Inc. Imidazopyridazine compounds
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8400863D0 (en) * 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
DE19632549A1 (de) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
DE19850701A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
DE19932315A1 (de) 1999-07-10 2001-01-11 Merck Patent Gmbh Benzoylpyridazine

Also Published As

Publication number Publication date
CA2465746A1 (en) 2003-05-15
RU2004117171A (ru) 2006-01-10
US7141572B2 (en) 2006-11-28
CN1585641A (zh) 2005-02-23
CA2465746C (en) 2011-09-06
ZA200404387B (en) 2006-02-22
AU2002363368B2 (en) 2007-12-13
US20060270676A1 (en) 2006-11-30
KR20050035177A (ko) 2005-04-15
HUP0401747A2 (hu) 2005-01-28
ES2268157T3 (es) 2007-03-16
PL369738A1 (en) 2005-05-02
BR0213683A (pt) 2004-10-26
AR040629A1 (es) 2005-04-13
RU2302412C2 (ru) 2007-07-10
WO2003039548A1 (en) 2003-05-15
JP5116940B2 (ja) 2013-01-09
JP2005511595A (ja) 2005-04-28
EP1441730B1 (en) 2006-08-09
DE60213841T2 (de) 2007-02-15
US20040261190A1 (en) 2004-12-30
EP1441730A1 (en) 2004-08-04
US7544684B2 (en) 2009-06-09
HUP0401747A3 (en) 2005-06-28
MXPA04004263A (es) 2004-07-08
ATE335486T1 (de) 2006-09-15
KR100898894B1 (ko) 2009-05-21
AU2002363368B9 (en) 2003-05-19
DE60213841D1 (de) 2006-09-21

Similar Documents

Publication Publication Date Title
MY129491A (en) Hydrazono-malonitriles
BR0311343A (pt) Derivados de piridazina
PL372316A1 (en) Glutaminyl based dpiv inhibitors
MY132106A (en) New pyridazin-3(2h)-one derivatives
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
GB0305142D0 (en) Synthesis
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
WO2002102313A3 (en) Pyrimidine inhibitors of phosphodiesterase (pde) 7
EP1864975A3 (en) Nicotinamide derivates useful as P38 inhibitors
GEP20084329B (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension
GB0305704D0 (en) Radiofluorination methods
SI1070056T1 (en) Phthalazinone pde iii/iv inhibitors
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
TW200407320A (en) Macrocyclic compounds useful as pharmaceuticals
GB0217757D0 (en) Novel compounds
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
DE602004008895D1 (en) Dpp-iv-hemmer
MXPA03009750A (es) Compuestos quimicos.
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
IL181267A0 (en) Vla-4 antagonists
MXPA03001356A (es) Nuevos agentes inhibidores de beta-amiloides, procedimientos para su preparacion y su uso como medicamentos.
SI1377574T1 (enExample)
SE9803773D0 (sv) Compounds
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.